[TAB]
REFERENCIAS
(1) The European Public Assessment Report for Byetta. Disponible en
http://www.emea.europa.eu/humandocs/Humans/EPAR/byetta/byetta.htm.
Acceso desde el 5 de julio de 2007.
(2) Barnett AH, Trautmann M, Burger J, Johns D, Kim D, Brodows R, Festa
A, Roberts A. A comparison of exenatide and insulin glargine in
patients using a single oral antidiabetic agent. Datos presentados
en la 42 Reunión Anual de la European Association of the Study of
Diabetes. 16 de septirmbre de 2006.
(3) Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG.
Exenatide versus insulin glargine in patients withsuboptimally
controlled type 2 diabetes: A randomized trial. Annals of Internal
Medicine 2005; 143(8):559-69.
(4) Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows B,
Trautmann M. A comparison of twice-daily exenatide and biphasic
insulin aspart in patients with type 2 diabetes who were
suboptimally controlled with sulfonylurea and metformin: A
noninferiority study. Diabetologia 2007; 50:259-267
(5) Trautmann ME., Burger J., Johns D., Brodows R., Okerson T., Roberts
A., and Barnett A. Less hypoglycemia with exenatide versus insulin
glargine, despite similar HbA1c improvement, in patients with T2DM
adjunctively treated with metformin. Datos presentados en las 67
Sesiones Científicas de la American Diabetes Association, 24 de
junio de 2007, Abstract # 0172-OR.
(6) The International Diabetes Federation Diabetes Atlas. Disponible en:
http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-
87B73F80BC22682A. Accesible desde el 14 de junio de 2007.
(7) The International Diabetes Federation, Prevalence / All diabetes.
Disponible en http://www.eatlas.idf.org/Prevalence/All_diabetes/.
(8) Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet,
sulfonylurea, metformin, or insulin in patients with type 2 diabetes
mellitus: progressive requirement for multiple therapies (UKPDS 49).
JAMA 1999; 281(21):2005-2012.
(9) The International Diabetes Federation, Complications. Disponible en
http://www.eatlas.idf.org/Complications/
(10) The International Diabetes Federation, Diabetes Atlas, Second
edition. The Economic Impact of Diabetes. 2003:186.
[FTAB]
(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO )
Medios, Derin Denham de Eli Lilly and Company, +1-317-277-6749, o móvil, +1-317-370-1435; o Alice Bahner Izzo de Amylin, +1-858-642-7272, o móvil, +1-858-232-9072. Foto: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO , PRN Photo Desk, photodesk@prnewswire.com
